Laboratory Corp. of America Holdings (NYSE:LH) CFO Glenn A. Eisenberg sold 8,400 shares of Laboratory Corp. of America stock in a transaction on Monday, February 12th. The stock was sold at an average price of $167.36, for a total value of $1,405,824.00. Following the completion of the sale, the chief financial officer now directly owns 15,931 shares of the company’s stock, valued at approximately $2,666,212.16. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Shares of Laboratory Corp. of America Holdings (LH) traded up $1.07 on Wednesday, hitting $172.08. The company had a trading volume of 264,920 shares, compared to its average volume of 651,748. The company has a quick ratio of 1.20, a current ratio of 1.31 and a debt-to-equity ratio of 0.93. Laboratory Corp. of America Holdings has a one year low of $134.10 and a one year high of $181.71. The company has a market capitalization of $17,152.28, a price-to-earnings ratio of 14.13, a P/E/G ratio of 1.48 and a beta of 0.93.
Laboratory Corp. of America (NYSE:LH) last issued its quarterly earnings data on Tuesday, February 6th. The medical research company reported $2.45 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.38 by $0.07. Laboratory Corp. of America had a return on equity of 16.30% and a net margin of 12.15%. The company had revenue of $2.70 billion during the quarter, compared to analyst estimates of $2.70 billion. During the same quarter in the previous year, the company posted $2.15 earnings per share. Laboratory Corp. of America’s revenue was up 13.2% compared to the same quarter last year. research analysts anticipate that Laboratory Corp. of America Holdings will post 11.53 earnings per share for the current fiscal year.
A number of research firms have commented on LH. Goldman Sachs Group began coverage on Laboratory Corp. of America in a report on Monday, January 29th. They issued a “buy” rating and a $205.00 target price for the company. Mizuho set a $178.00 target price on Laboratory Corp. of America and gave the stock a “hold” rating in a report on Wednesday, January 24th. ValuEngine raised Laboratory Corp. of America from a “hold” rating to a “buy” rating in a report on Friday, February 2nd. Zacks Investment Research raised Laboratory Corp. of America from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th. Finally, Robert W. Baird set a $183.00 target price on Laboratory Corp. of America and gave the stock a “hold” rating in a report on Thursday, February 8th. Six equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. Laboratory Corp. of America currently has an average rating of “Buy” and a consensus price target of $180.73.
About Laboratory Corp. of America
Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).
Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.